Infect Chemother.  2013 Mar;45(1):105-107.

Serratia marcescens Peritonitis in a Diabetic Patient Receiving Continuous Ambulatory Peritoneal Dialysis

• Kang JH
• Kim MJ
• Kang YU
• Kim CS
• Choi JS
• Bae EH
• Ma SK
• Kim SW

Abstract

We report a case of Serratia marcescens peritonitis in a 45-year-old man with insulin-dependent diabetes mellitus undergoing continuous ambulatory peritoneal dialysis (CAPD). The patient presented with abdominal pain and cloudy dialysate. Empiric antibiotic therapy was initiated intraperitoneally with cefazolin and ceftazidime for 5 days. Cultures of the dialysate revealed S. marcescens, and the treatment was subsequently changed to gentamicin and ceftazidime. Oral ciprofloxacin was also added. The patient's abdominal pain and the dialysate white blood cell (WBC) count, however, did not improve. The indwelling CAPD catheter was therefore removed. This is an unusual case report in the Korean literature of S. marcescens peritonitis in a patient receiving CAPD.

Keyword

Serratia marcescens; Continuous ambulatory peritoneal dialysis; Peritonitis

MeSH Terms

Abdominal Pain
Catheters
Cefazolin
Ceftazidime
Ciprofloxacin
Diabetes Mellitus, Type 1
Gentamicins
Humans
Leukocytes
Peritoneal Dialysis, Continuous Ambulatory
Peritonitis
Serratia
Serratia marcescens
Cefazolin
Ceftazidime
Ciprofloxacin
Gentamicins

Reference

1. Hejazi A, Falkiner FR. Serratia marcescens. J Med Microbiol. 1997. 46:903–912.

2. Saklayen MG. CAPD peritonitis. Incidence, pathogens, diagnosis, and management. Med Clin North Am. 1990. 74:997–1010.

3. Leblanc M. Oral ciprofloxacin to treat bacterial peritonitis associated with peritoneal dialysis. Clin Nephrol. 1997. 47:350.

4. Vas S. Changing picture of peritonitis in peritoneal dialysis. Am J Kidney Dis. 2000. 36:1057–1058.

5. Jarvis EM, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister KM, Johnson DW. Predictors, treatment, and outcomes of non-Pseudomonas Gram-negative peritonitis. Kidney Int. 2010. 78:408–414.

6. Szeto CC, Leung CB, Chow KM, Kwan BC, Law MC, Wang AY, Lui SF, Li PK. Change in bacterial etiology of peritoneal dialysis-related peritonitis over 10 years: experience from a centre in South-East Asia. Clin Microbiol Infect. 2005. 11:837–839.

7. Krishnan M, Thodis E, Ikonomopoulos D, Vidgen E, Chu M, Bargman JM, Vas SI, Oreopoulos DG. Predictors of outcome following bacterial peritonitis in peritoneal dialysis. Perit Dial Int. 2002. 22:573–581.

8. Wilhelmi I, Bernaldo de Quirós JC, Romero-Vivas J, Duarte J, Rojo E, Bouza E. Epidemic outbreak of Serratia marcescens infection in a cardiac surgery unit. J Clin Microbiol. 1987. 25:1298–1300.

9. Haddy RI, Mann BL, Nadkarni DD, Cruz RF, Elshoff DJ, Buendia FC, Domers TA, Oberheu AM. Nosocomial infection in the community hospital: severe infection due to Serratia species. J Fam Pract. 1996. 42:273–277.

10. Nikolaidis P. Newer quinolones in the treatment of continuous ambulatory peritoneal dialysis (CAPD) related infections. Perit Dial Int. 1990. 10:127–133.

11. Lee SH, Noh HJ, Shin SK, Lee IH, Kang SW, Choi KH, Ha SK, Han DS, Lee HY. Clinical characteristics of relapsing peritonitis in CAPD patients. Korean J Nephrol. 1997. 16:738–746.

12. Bouza E, García de la Torre M, Erice A, Cercenado E, Loza E, Rodríguez-Créixems M. Serratia bacteremia. Diagn Microbiol Infect Dis. 1987. 7:237–247.

13. Chow KM, Szeto CC, Leung CB, Kwan BC, Law MC, Li PK. A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Perit Dial Int. 2005. 25:374–379.

14. Connacher AA, Old DC, Phillips G, Stewart WK, Grimont F, Grimont PA. Recurrent peritonitis caused by Serratia marcescens in a diabetic patient receiving continuous ambulatory peritoneal dialysis. J Hosp Infect. 1988. 11:155–160.